TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28228151

Group type: EXPERIMENTAL
Intervention: Activate intervention (4 nurse-led consultations over 3 months, integrating 17 behaviour change techniques)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 279
Study: 26251078

Group type: EXPERIMENTAL
Intervention: Non-O blood groups
Number of subjects: 1835
Study: 24146467

Group type: EXPERIMENTAL
Intervention: Saponin SC-2 from Solanum chrysotrichum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketoconazole
Number of subjects: 0
Study: 20864423

Group type: EXPERIMENTAL
Intervention: Early enteral 5% glucose infusion (25 ml h(‐1) via jejunostomy tube initiated 6h after surgery)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (peripheral parenteral nutrition for seven post-operation days)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Early enteral 5% glucose infusion
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study: 18284670

Group type: EXPERIMENTAL
Intervention: Web-based self-help course (8-week duration, moderated, individual feedback via e-mail)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Web-based self-help course
Number of subjects: 286

Group type: COMPARATOR
Intervention: Control group (wait-list)
Number of subjects: 286
Study: 14594748

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/day for the first 28 days and 10 mg/day thereafter)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 9707356

Group type: EXPERIMENTAL
Intervention: 50 mg PETN
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 80 mg PETN
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.4 mg GTN
Number of subjects: 12
Study: 7536138

Group type: EXPERIMENTAL
Intervention: Arginine, RNA, and omega-3 fatty acids supplemented diet
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo diet
Number of subjects: 42
Study: 2650539

Group type: EXPERIMENTAL
Intervention: 10 mg lovastatin twice daily for 6 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 mg lovastatin twice daily for 6 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 40 mg lovastatin twice daily for 6 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 40 mg lovastatin twice daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 mg lovastatin twice daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 mg lovastatin twice daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo for the first 6 weeks followed by stepped doses of lovastatin
Number of subjects: 10
Study: 361152

Group type: EXPERIMENTAL
Intervention: Acid mixture
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Alkali mixture
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 31583989

Group type: EXPERIMENTAL
Intervention: MDD participants with childhood maltreatment (DM+)
Number of subjects: 285

Group type: COMPARATOR
Intervention: MDD participants without maltreatment (DM-)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Healthy participants without maltreatment (HM-)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Post-treatment remitted DM+
Number of subjects: 285

Group type: COMPARATOR
Intervention: Post-treatment remitted DM-
Number of subjects: 285
Study: 31102328

Group type: EXPERIMENTAL
Intervention: High oxygen therapy (≥96% SpO2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low oxygen therapy (90–92% SpO2)
Number of subjects: 50
Study: 26920551

Group type: EXPERIMENTAL
Intervention: Perceived needs for housing
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Perceived needs for substance treatment services
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Perceived needs for assistance/benefits
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Perceived needs for mental health counseling
Number of subjects: 165
Study: 25500985

Group type: EXPERIMENTAL
Intervention: Limbal incision
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fornix incision
Number of subjects: 120

Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 120
Study: 23271030

Group type: COMPARATOR
Intervention: Sublingual sufentanil 15 µg
Number of subjects: 195

Group type: COMPARATOR
Intervention: Sublingual sufentanil 10 µg
Number of subjects: 195

Group type: COMPARATOR
Intervention: Sublingual sufentanil 5-15 µg
Number of subjects: 195
Study: 21980881

Group type: EXPERIMENTAL
Intervention: Deepwave treatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham treatment (Control)
Number of subjects: 23
Study: 19153678

Group type: EXPERIMENTAL
Intervention: Strontium ranelate (2 g/day)
Number of subjects: 1649

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1649
Study: 16709243

Group type: EXPERIMENTAL
Intervention: Educational intervention consisting of 18 sessions in 6 separate programmes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethnic control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single white control group
Number of subjects: 0
Study: 14748817

Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg daily for 5 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11695526

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerebellar patients
Number of subjects: 0
Study: 9042992

Group type: EXPERIMENTAL
Intervention: Ondansetron (0.3 mg/kg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.3 mg/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (sterile saline)
Number of subjects: 36
Study: 16353616

Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg/d)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: COMPARATOR
Intervention: Both groups (Fluoxetine and Placebo)
Number of subjects: 38
Study: 30087555

Group type: EXPERIMENTAL
Intervention: 120 mg fimasartan
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Coadministration of fimasartan and atorvastatin
Number of subjects: 36
Study: 25763853

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of hyaluronic acid (HA) post-operatively
Number of subjects: 35

Group type: COMPARATOR
Intervention: Arthroscopic microfracture surgery alone
Number of subjects: 35
Study: 23804543

Group type: EXPERIMENTAL
Intervention: RYGB surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Obese subjects and obese T2DM patients
Number of subjects: 0
Study: 23270248

Group type: EXPERIMENTAL
Intervention: Kang'ai injection with chemotherapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Chemotherapy only (Control)
Number of subjects: 42
Study: 20440030

Group type: EXPERIMENTAL
Intervention: Golfing
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lawn Mowing
Number of subjects: 18
Study: 19855323

Group type: EXPERIMENTAL
Intervention: Weightlifting
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Plyometrics
Number of subjects: 29

Group type: COMPARATOR
Intervention: Weight training
Number of subjects: 29
Study: 16480123

Group type: EXPERIMENTAL
Intervention: Collective self-prime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relational self-prime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Private self-prime
Number of subjects: 0
Study: 12759389

Group type: EXPERIMENTAL
Intervention: Beta-carotene (25 mg)
Number of subjects: 864
Study: 10974724

Group type: EXPERIMENTAL
Intervention: Single 8-Gy fraction
Number of subjects: 90

Group type: COMPARATOR
Intervention: 20 Gy in five fractions
Number of subjects: 90
Study: 9092145

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 1749

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1749
Study: 8481254

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) with or without dipyridamole (D)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Dipyridamole (D)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Anticoagulants (AC)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) + Anticoagulants (AC)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Low (100 mg) to medium (325 mg) daily aspirin dosage
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Early postoperative treatment (< or = 6 h)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Preoperative administration of aspirin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Any antithrombotic therapy
Number of subjects: 17
Study: 3538880

Group type: EXPERIMENTAL
Intervention: 2% hydroxypropyl methylcellulose
Number of subjects: 70

Group type: COMPARATOR
Intervention: 1% sodium hyaluronate
Number of subjects: 70
Study: 29672392

Group type: EXPERIMENTAL
Intervention: Hyperoxygenated fatty acids (HOFAs) treatment
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control (no HOFAs applied)
Number of subjects: 174
Study: 26969090

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg per day orally for 54 weeks
Number of subjects: 1943

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice per day orally for 54 weeks
Number of subjects: 1943

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1943
Study: 25377986

Group type: EXPERIMENTAL
Intervention: Electrocautery (EC)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Radiofrequency tissue reduction (RFTR)
Number of subjects: 36
Study: 22435470

Group type: EXPERIMENTAL
Intervention: SLS-free dentifrice
Number of subjects: 90

Group type: COMPARATOR
Intervention: SLS-containing dentifrice (SLS-A and SLS-B)
Number of subjects: 90
Study: 20485880

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (zinc and vitamin A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18517133

Group type: EXPERIMENTAL
Intervention: Trimecaine 50 mg with 4 mg morphine administered epidurally in 8 hour intervals
Number of subjects: 150

Group type: COMPARATOR
Intervention: Bupivacaine 0.25% and fentanyl 2 microg/ml administered at an infusion rate of 8 ml/h
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Trimecaine with morphine
Number of subjects: 150
Study: 16111417

Group type: EXPERIMENTAL
Intervention: Coblation tonsillotomy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Coblation tonsillectomy
Number of subjects: 18
Study: 11950105

Group type: EXPERIMENTAL
Intervention: Activation of illness concern
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical control for state anxiety
Number of subjects: 0
Study: 10522523

Group type: EXPERIMENTAL
Intervention: Low-dose ACTH (0.005 mg/kg per day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High-dose ACTH (0.025 mg/kg per day)
Number of subjects: 25
Study: 8748907

Group type: EXPERIMENTAL
Intervention: Chloral hydrate 70 mg/kg (group A)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Chloral hydrate 100 mg/kg (group B)
Number of subjects: 97
Study: 1823061

Group type: EXPERIMENTAL
Intervention: Modified distal splenorenal shunt (DSRS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy (ES)
Number of subjects: 100
Study: 7025554

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 12‐50 microgram/min of salbutamol (Ventoline) and 4 mg orally at 4‐hour intervals
Number of subjects: 108

Group type: COMPARATOR
Intervention: Fenoterol, 3‐4 microgram/min and subsequently 5 mg orally at 4‐hour intervals
Number of subjects: 108
Study: 30094611

Group type: EXPERIMENTAL
Intervention: Plate fixation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramedullary pin fixation
Number of subjects: 0
Study: 28230742

Group type: EXPERIMENTAL
Intervention: GLU + FRU (1.2 g∙min‐1 glucose + 0.6 g∙min‐1 fructose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GLU + SUC (0.6 g∙min‐1 glucose + 1.2 g∙min‐1 sucrose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: GLU (1.8 g∙min‐1 glucose)
Number of subjects: 10
Study: 25912752

Group type: EXPERIMENTAL
Intervention: Trabectedin 3-hour infusion (T3h)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Trabectedin 24-hour infusion (T24h)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 133
Study: 23360657

Group type: EXPERIMENTAL
Intervention: Relaxation breathing exercise (RB)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control breathing (CB)
Number of subjects: 26
Study: 21355070

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 100
Study: 18808733

Group type: EXPERIMENTAL
Intervention: Home HIOH intervention
Number of subjects: 415

Group type: COMPARATOR
Intervention: Telephone HIOH intervention
Number of subjects: 415

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 415
Study: 17066400

Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15513495

Group type: EXPERIMENTAL
Intervention: Continuous intraarticular morphine 20 mg/mL, 0.5 mL plus ropivacaine 2 mg/mL, 100 mL; bolus 20 mL and 2 mL/hour from 24 to 72 hours postoperatively (group 2)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Double the dose of continuous intraarticular morphine and ropivacaine (4 mL/hour from 24 to 72 hours postoperatively) (group 3)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Standard postoperative analgesics (group 1)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Continuous intraarticular morphine and ropivacaine (group 2 and group 3)
Number of subjects: 154
Study: 10930961

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 28

Group type: COMPARATOR
Intervention: Saquinavir
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ritonavir
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sildenafil coadministered with saquinavir or ritonavir
Number of subjects: 28
Study: 9049554

Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 8339808

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study: 2883777

Group type: EXPERIMENTAL
Intervention: Vasodilators (including nitrates and alpha-receptor blocking agents)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Converting enzyme inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31506921

Group type: EXPERIMENTAL
Intervention: Tracker on
Number of subjects: 8
Study: 28234719

Group type: EXPERIMENTAL
Intervention: Upper and Lower Body (ULB) PAP
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Lower Body (LB) PAP
Number of subjects: 11

Group type: COMPARATOR
Intervention: Usual Competition (CON) Warm-Up Routine
Number of subjects: 11
Study: 28110949

Group type: EXPERIMENTAL
Intervention: Oral acetazolamide (500 mg) administration 1 hour preoperatively
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral acetazolamide (500 mg) administration 3 hours postoperatively
Number of subjects: 90

Group type: COMPARATOR
Intervention: No acetazolamide administration
Number of subjects: 90
Study: 25682211

Group type: EXPERIMENTAL
Intervention: Counselor-assisted problem solving (CAPS), predominantly online intervention
Number of subjects: 132

Group type: COMPARATOR
Intervention: Internet resource comparison (control group)
Number of subjects: 132
Study: 24101198

Group type: EXPERIMENTAL
Intervention: Visual action effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proprioceptive action effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermodal integration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perturbation of cursor amplitude or hand amplitude
Number of subjects: 0
Study: 21418045

Group type: EXPERIMENTAL
Intervention: Spinal hyperbaric bupivacaine 7.5 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Spinal hyperbaric bupivacaine 7.5 mg followed by epidural volume extension with saline 5 ml
Number of subjects: 90

Group type: COMPARATOR
Intervention: Spinal hyperbaric bupivacaine 10 mg without epidural volume extension
Number of subjects: 90
Study: 18581058

Group type: EXPERIMENTAL
Intervention: Current smokers (317 patients)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Non-smokers (182 patients)
Number of subjects: 499
Study: 17175547

Group type: EXPERIMENTAL
Intervention: Combined Oral Contraceptives (COC)
Number of subjects: 4200

Group type: EXPERIMENTAL
Intervention: Norethindrone Enanthate (NET-EN)
Number of subjects: 4200

Group type: EXPERIMENTAL
Intervention: Depot Medroxyprogesterone Acetate (DMPA)
Number of subjects: 4200

Group type: COMPARATOR
Intervention: No hormonal method
Number of subjects: 4200

Group type: EXPERIMENTAL
Intervention: DMPA duration
Number of subjects: 4200
Study: 15124187

Group type: EXPERIMENTAL
Intervention: Endometrial thickness measurement (transvaginal sonography)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Endometrial thickness > 9 mm
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Time since menopause < 5 years
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Time since menopause > 15 years
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Cutoff points for diagnostic biopsy
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Multiple logistic regression analysis
Number of subjects: 95
Study: 12136518

Group type: EXPERIMENTAL
Intervention: Breast conservation therapy (BCT) with lumpectomy and radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by BCT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiation for early breast cancer patients with 1 to 3 positive lymph nodes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of chest wall and regional lymphatic irradiation to adjuvant systemic therapy
Number of subjects: 0
Study: 10051931

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 31

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 31
Study: 7977523

Group type: EXPERIMENTAL
Intervention: Nafarelin therapy (200 micrograms intranasally twice a day for 3 months)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Nafarelin therapy (200 micrograms intranasally twice a day for 6 months)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Nafarelin therapy (both 3 and 6 months)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Nafarelin therapy
Number of subjects: 173
Study: 2599698

Group type: EXPERIMENTAL
Intervention: Cemented Charnley prosthesis
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Non-cemented HP-Garches prosthesis
Number of subjects: 21
Study: 29655290

Group type: EXPERIMENTAL
Intervention: Empagliflozin 5 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 27
Study: 29141361

Group type: EXPERIMENTAL
Intervention: Probucol 500 mg twice daily for day 0 to day 3 after PCI
Number of subjects: 641

Group type: COMPARATOR
Intervention: Control group (conventional therapy only)
Number of subjects: 641
Study: 25729164

Group type: EXPERIMENTAL
Intervention: Hip exercises
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 78
Study: 23607895

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Treatment (CBT)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Treatment supported by Information and Communication Technologies (CBT + ICT)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 180
Study: 21310077

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galactose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative therapy (lisinopril, losartan, atorvastatin)
Number of subjects: 0
Study: 19845453

Group type: EXPERIMENTAL
Intervention: TAPP (Transabdominal Preperitoneal hernia repair)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TEP (Totally Extraperitoneal hernia repair)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both TAPP and TEP procedures
Number of subjects: 40
Study: 17098133

Group type: EXPERIMENTAL
Intervention: IVNC
Number of subjects: 26

Group type: COMPARATOR
Intervention: DCMP
Number of subjects: 26
Study: 15378097

Group type: EXPERIMENTAL
Intervention: Exercise intervention (moderate exercise programs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise intervention (referrals to physical therapy and/or rehabilitation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise intervention (encouraging physical activity)
Number of subjects: 0
Study: 11331630

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (40 microg s.c. per day) initiated on cycle day 2 followed by exogenous gonadotrophins on cycle day 3
Number of subjects: 48

Group type: COMPARATOR
Intervention: GnRH antagonist (cetrorelix, 0.25 mg daily during late follicular phase)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 9383647

Group type: EXPERIMENTAL
Intervention: Child Behavior Check List (CBCL)
Number of subjects: 1964

Group type: EXPERIMENTAL
Intervention: Diagnostic Interview Schedule for Children (DISC)
Number of subjects: 1964
Study: 8579131

Group type: EXPERIMENTAL
Intervention: Proliferating cell nuclear antigen (PCNA) immunohistochemical analysis
Number of subjects: 22
Study: 3127846

Group type: EXPERIMENTAL
Intervention: Marijuana containing 2.7% delta 9‐THC (M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Marijuana containing 0.0% delta 9‐THC (P)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Marijuana containing 0.9% delta 9‐THC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Marijuana containing 1.4% delta 9‐THC
Number of subjects: 0
Study: 30866853

Group type: EXPERIMENTAL
Intervention: Healthy children
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Children with ARIs
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Pneumococci non-susceptible to multiple beta-lactams
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Serotype 19F
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Daycare attendance
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: PCV13 vaccine serotypes
Number of subjects: 883
Study: 28395984

Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT) including neurodynamic techniques, functional massage, and carpal bone mobilization
Number of subjects: 140

Group type: COMPARATOR
Intervention: Electrophysical Modalities (EM) including laser and ultrasound therapy
Number of subjects: 140